{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:52Z","timestamp":1792271392088,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009992","name":"Seattle Children's Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009992","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jcf.2024.02.015","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T08:30:21Z","timestamp":1709713821000},"page":"490-498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5653-2220","authenticated-orcid":false,"given":"Jennifer T","family":"Duong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary S","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4884","authenticated-orcid":false,"given":"Carson","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-6992","authenticated-orcid":false,"given":"Stephen J","family":"Salipante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2969-5518","authenticated-orcid":false,"given":"George M","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-7960","authenticated-orcid":false,"given":"David","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8864-6751","authenticated-orcid":false,"given":"Lucas R","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Narkewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0371-0986","authenticated-orcid":false,"given":"Nicole","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.02.015_bib0001","series-title":"Cystic fibrosis foundation patient registry annual data report 2021","year":"2021"},{"issue":"2","key":"10.1016\/j.jcf.2024.02.015_bib0002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2012.11.010","article-title":"Cirrhosis and other liver disease in cystic fibrosis","volume":"12","author":"Flass","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.015_bib0003","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.1840360613","article-title":"Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome","volume":"36","author":"Colombo","year":"2002","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.015_bib0004","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.510300527","article-title":"Natural history of liver disease in cystic fibrosis","volume":"30","author":"Lindblad","year":"1999","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.015_bib0005","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(16)30241-2","article-title":"The intestinal microbiome and paediatric liver disease","volume":"2","author":"Leung","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jcf.2024.02.015_bib0006","doi-asserted-by":"crossref","first-page":"G474","DOI":"10.1152\/ajpgi.00055.2012","article-title":"CFTR dysfunction predisposes to fibrotic liver disease in a murine model","volume":"303","author":"Martin","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"10.1016\/j.jcf.2024.02.015_bib0007","doi-asserted-by":"crossref","first-page":"G491","DOI":"10.1152\/ajpgi.00452.2003","article-title":"Induction of colitis in cftr-\/- mice results in bile duct injury","volume":"287","author":"Blanco","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"12","key":"10.1016\/j.jcf.2024.02.015_bib0008","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/hep4.1266","article-title":"Diet-induced dysbiosis and genetic background synergize with cystic fibrosis transmembrane conductance regulator deficiency to promote cholangiopathy in mice","volume":"2","author":"Debray","year":"2018","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.015_bib0009","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MPG.0b013e3181d1b013","article-title":"Evidence of intestinal inflammation in patients with cystic fibrosis","volume":"51","author":"Werlin","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.jcf.2024.02.015_bib0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/MPG.0000000000000683","article-title":"Intestinal inflammation and impact on growth in children with cystic fibrosis","volume":"60","author":"Dhaliwal","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.015_bib0011","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/adc.65.6.585","article-title":"Small intestinal permeability and orocaecal transit time in cystic fibrosis","volume":"65","author":"Dalzell","year":"1990","journal-title":"Arch Dis Child"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.015_bib0012","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jcf.2012.10.003","article-title":"Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota","volume":"12","author":"Duytschaever","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2024.02.015_bib0013","doi-asserted-by":"crossref","first-page":"e61176","DOI":"10.1371\/journal.pone.0061176","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients","volume":"8","author":"Schippa","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.015_bib0014","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1038\/s41598-017-06880-y","article-title":"A pilot study demonstrating the altered gut microbiota functionality in stable adults with Cystic Fibrosis","volume":"7","author":"Fouhy","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2024.02.015_bib0015","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-022-07812-1","article-title":"Cystic Fibrosis-related gut dysbiosis: a systematic review","author":"Caley","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.015_bib0016","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/jcm11030649","article-title":"Intestinal inflammation and alterations in the gut microbiota in cystic fibrosis: a review of the current evidence, pathophysiology and future directions","volume":"11","author":"Tam","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2024.02.015_bib0017","doi-asserted-by":"crossref","first-page":"22493","DOI":"10.1038\/srep22493","article-title":"Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis","volume":"6","author":"Manor","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.jcf.2024.02.015_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116967","article-title":"Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis","volume":"10","author":"Flass","year":"2015","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.015_bib0019","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"10.1016\/j.jcf.2024.02.015_bib0020","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"S1569-1993","author":"Schwarzenberg","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.02.015_bib0021","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2021.02.003","article-title":"PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy","volume":"20","author":"Nichols","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2024.02.015_bib0022","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nmeth.2066","article-title":"Metagenomic microbial community profiling using unique clade-specific marker genes","volume":"9","author":"Segata","year":"2012","journal-title":"Nat Method"},{"issue":"2","key":"10.1016\/j.jcf.2024.02.015_bib0023","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41591-019-0714-x","article-title":"Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure","volume":"26","author":"Hayden","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.015_bib0024","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/cid\/cit715","article-title":"Escherichia coli dysbiosis correlates with gastrointestinal dysfunction in children with cystic fibrosis","volume":"58","author":"Hoffman","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcf.2024.02.015_bib0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.anaerobe.2014.05.003","article-title":"The influence of oral Veillonella species on biofilms formed by Streptococcus species","volume":"28","author":"Mashima","year":"2014","journal-title":"Anaerobe"},{"issue":"12","key":"10.1016\/j.jcf.2024.02.015_bib0026","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1128\/JB.01631-09","article-title":"Central role of the early colonizer Veillonella sp. in establishing multispecies biofilm communities with initial, middle, and late colonizers of enamel","volume":"192","author":"Periasamy","year":"2010","journal-title":"J Bacteriol"},{"issue":"12","key":"10.1016\/j.jcf.2024.02.015_bib0027","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1128\/CVI.00310-09","article-title":"Receptor recognition of and immune intracellular pathways for Veillonella parvula lipopolysaccharide","volume":"16","author":"Matera","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"12","key":"10.1016\/j.jcf.2024.02.015_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114277","article-title":"Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota","volume":"9","author":"van den Bogert","year":"2014","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.015_bib0029","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41420-022-01015-3","article-title":"Overabundance of Veillonella parvula promotes intestinal inflammation by activating macrophages via LPS-TLR4 pathway","volume":"8","author":"Zhan","year":"2022","journal-title":"Cell Death Discov"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.015_bib0030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/hep.27489","article-title":"Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jcf.2024.02.015_bib0031","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/j.1462-5822.2004.00420.x","article-title":"Candida albicans and Streptococcus salivarius modulate IL-6, IL-8, and TNF-alpha expression and secretion by engineered human oral mucosa cells","volume":"6","author":"Mostefaoui","year":"2004","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.jcf.2024.02.015_bib0032","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.3389\/fmicb.2018.03166","article-title":"Disorganized Gut Microbiome Contributed to Liver Cirrhosis Progression: a Meta-Omics-Based Study","volume":"9","author":"Shao","year":"2018","journal-title":"Front Microbiol"},{"issue":"7516","key":"10.1016\/j.jcf.2024.02.015_bib0033","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome in liver cirrhosis","volume":"513","author":"Qin","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jcf.2024.02.015_bib0034","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/ecco-jcc\/jjab020","article-title":"The Composition and Metabolic Potential of the Human Small Intestinal Microbiota Within the Context of Inflammatory Bowel Disease","volume":"15","author":"Ruigrok","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"25","key":"10.1016\/j.jcf.2024.02.015_bib0035","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.3748\/wjg.v23.i25.4548","article-title":"Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis","volume":"23","author":"Bajer","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.015_bib0036","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/jinf.2002.1034","article-title":"Spontaneous bacterial peritonitis from Streptococcus salivarius in a compromised host","volume":"45","author":"Peterson","year":"2002","journal-title":"J Infect"},{"issue":"7","key":"10.1016\/j.jcf.2024.02.015_bib0037","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/00004836-200608000-00023","article-title":"Streptococcus salivarius bacteremia in a cirrhotic patient with neutropenia postesophageal variceal ligation","volume":"40","author":"Sass","year":"2006","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.jcf.2024.02.015_bib0038","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre","volume":"22","author":"Tewkesbury","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.02.015_bib0039","doi-asserted-by":"crossref","first-page":"e0010","DOI":"10.1097\/HC9.0000000000000010","article-title":"Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis","volume":"7","author":"Levitte","year":"2023","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.jcf.2024.02.015_bib0040","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcf.2021.07.018","article-title":"Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR","volume":"21","author":"Drummond","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcf.2024.02.015_bib0041","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.cgh.2018.10.046","article-title":"Obliterative Portal Venopathy Without Cirrhosis Is Prevalent in Pediatric Cystic Fibrosis Liver Disease With Portal Hypertension","volume":"17","author":"Wu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:30:49Z","timestamp":1777649449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1569199324000298"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.015","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor\/tezacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}